Aswani P, Krishna and Sebastian , John and Puja Laxmanrao , Shinde and Rashmi , Mishra (2021) Proteo-transcriptomics meta-analysis identifies SUMO2 as a promising target in glioblastoma multiforme therapeutics. Cancer cell international, 21 (1). ISSN 1475-2867

Text Proteo-transcriptomics(Cancer Cell Int).pdf Restricted to Registered users only Download (5Mb) | Request a copy

Abstract

Proteo-transcriptomics meta-analysis identifies SUMO2 as a promising target in glioblastoma multiforme therapeutics Aswani P. Krishna, Sebastian John, [...], and Rashmi Mishra Additional article information Associated Data Supplementary Materials Data Availability Statement Abstract Background Glioblastoma multiforme (GBM) is a deadly brain tumour with minimal survival rates due to the ever-expanding heterogeneity, chemo and radioresistance. Kinases are known to crucially drive GBM pathology; however, a rationale therapeutic combination that can simultaneously inhibit multiple kinases has not yet emerged successfully. Results Here, we analyzed the GBM patient data from several publicly available repositories and deduced hub GBM kinases, most of which were identified to be SUMOylated by SUMO2/3 isoforms. Not only the hub kinases but a significant proportion of GBM upregulated genes involved in proliferation, metastasis, invasion, epithelial-mesenchymal transition, stemness, DNA repair, stromal and macrophages maintenance were also identified to be the targets of SUMO2 isoform. Correlatively, high expression of SUMO2 isoform was found to be significantly associated with poor patient survival.

Item Type:	Article
Uncontrolled Keywords:	Cancer drug target discovery; Glioblastoma multiforme; Kinases and cancer; SUMO2; TCGA.
Subjects:	Molecular Neurobiology
Depositing User:	Central Library RGCB
Date Deposited:	02 Mar 2022 09:49
Last Modified:	02 Mar 2022 09:49
URI:	http://rgcb.sciencecentral.in/id/eprint/1134

Actions (login required)

View Item